Literature DB >> 16651421

Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis.

Tobias Peikert1, Ulrich Specks, Carol Farver, Serpil C Erzurum, Suzy A A Comhair.   

Abstract

A variety of melanoma antigen A (MAGE-A) genes are commonly detected in non-small cell lung cancers. Their biological function is not well characterized but may involve the regulation of apoptosis and cell cycle progression. We hypothesized that MAGE-A4 is involved in the regulation of apoptosis. To investigate this, expression of MAGE-A was evaluated. MAGE-A4 was expressed in 48% of non-small cell lung carcinomas. Ninety percent of lung carcinomas expressing MAGE-A4 were classified as squamous cell carcinomas and 10% were adenocarcinomas. Tumor-free surrounding lung tissue was negative for MAGE-A4. A molecular clone of MAGE-A4 derived from human lung cancer was stably expressed in human embryonic kidney cells (293 cells) to evaluate effects on cell death. Overexpression of MAGE-A4 increased apoptosis as measured by the apoptotic index (P < 0.0001) and caspase-3 activity (P < 0.002). Exposure to 25 micromol/L etoposide, a chemotherapeutic agent, increased the apoptotic effect (P < 0.0001). Furthermore, we show that MAGE-A4 silencing using a small interfering RNA approach results in decreased caspase-3 activity in the squamous cell lung cancer cell line H1703 by 58% (P = 0.0027) and by 24% (P = 0.028) in 293/MAGE-A4 cells. These findings suggest that MAGE-A4 expression may promote tumor cell death, sensitize malignancies to apoptotic stimuli, such as chemotherapeutic agents, and therefore may represent a tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651421     DOI: 10.1158/0008-5472.CAN-05-3327

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

2.  Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Authors:  Jun Yao; Otavia L Caballero; W K Alfred Yung; John N Weinstein; Gregory J Riggins; Robert L Strausberg; Qi Zhao
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

3.  MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.

Authors:  L Y Peche; M Scolz; M F Ladelfa; M Monte; C Schneider
Journal:  Cell Death Differ       Date:  2011-11-25       Impact factor: 15.828

4.  Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer.

Authors:  Manisha Bhutani; Ashutosh Kumar Pathak; Hongli Tang; You H Fan; Diane D Liu; J Jack Lee; Jonathan Kurie; Rodolfo C Morice; Waun Ki Hong; Li Mao
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

5.  Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11.

Authors:  Kinza Younas; Marcos Quintela; Samantha Thomas; Jetzabel Garcia-Parra; Lauren Blake; Helen Whiteland; Adnan Bunkheila; Lewis W Francis; Lavinia Margarit; Deyarina Gonzalez; R Steven Conlan
Journal:  J Mol Med (Berl)       Date:  2019-06-29       Impact factor: 4.599

6.  Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.

Authors:  Kunio Iura; Kenichi Kohashi; Nobuko Yasutake; Takeaki Ishii; Akira Maekawa; Hirofumi Bekki; Hiroshi Otsuka; Yuichi Yamada; Hidetaka Yamamoto; Yoshihiro Ohishi; Yoshihiro Matsumoto; Yukihide Iwamoto; Yoshinao Oda
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

7.  Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.

Authors:  Chad A Glazer; Ian M Smith; Michael F Ochs; Shahnaz Begum; William Westra; Steven S Chang; Wenyue Sun; Sheetal Bhan; Zubair Khan; Steven Ahrendt; Joseph A Califano
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

8.  Frequent MAGE mutations in human melanoma.

Authors:  Otavia L Caballero; Qi Zhao; Donata Rimoldi; Brian J Stevenson; Suzanne Svobodová; Sylvie Devalle; Ute F Röhrig; Anna Pagotto; Olivier Michielin; Daniel Speiser; Jedd D Wolchok; Cailian Liu; Tanja Pejovic; Kunle Odunsi; Francis Brasseur; Benoit J Van den Eynde; Lloyd J Old; Xin Lu; Jonathan Cebon; Robert L Strausberg; Andrew J Simpson
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

9.  High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival.

Authors:  Siya Zhang; Xiaolu Zhai; Gui Wang; Jian Feng; Huijun Zhu; Liqin Xu; Guoxin Mao; Jianfei Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

10.  Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Authors:  Teresa Cabezón; Irina Gromova; Pavel Gromov; Reza Serizawa; Vera Timmermans Wielenga; Niels Kroman; Julio E Celis; José M A Moreira
Journal:  Mol Cell Proteomics       Date:  2012-11-20       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.